Symbols / PEPG
PEPG Chart
About
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 445.14M |
| Enterprise Value | 288.26M | Income | -93.56M | Sales | — |
| Book/sh | 2.37 | Cash/sh | 2.38 | Dividend Yield | — |
| Payout | 0.00% | Employees | 57 | IPO | — |
| P/E | — | Forward P/E | -5.12 | PEG | — |
| P/S | — | P/B | 2.73 | P/C | — |
| EV/EBITDA | -2.98 | EV/Sales | — | Quick Ratio | 12.95 |
| Current Ratio | 13.15 | Debt/Eq | 10.69 | LT Debt/Eq | — |
| EPS (ttm) | -2.82 | EPS next Y | -1.26 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-02 | ROA | -34.09% |
| ROE | -62.25% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 68.75M |
| Shs Float | 40.18M | Short Float | 5.21% | Short Ratio | 3.89 |
| Short Interest | — | 52W High | 7.80 | 52W Low | 0.88 |
| Beta | 1.91 | Avg Volume | 708.74K | Volume | 267.77K |
| Target Price | $10.17 | Recom | Strong_buy | Prev Close | $6.32 |
| Price | $6.47 | Change | 2.45% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.17
Mean price target
2. Current target
$6.48
Latest analyst target
3. DCF / Fair value
$-13.67
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.48
Low
$3.00
High
$20.00
Mean
$10.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-25 | init | Oppenheimer | — → Outperform | $15 |
| 2026-02-18 | main | Guggenheim | Buy → Buy | $7 |
| 2025-11-13 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-10-27 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-09-30 | main | Wedbush | Outperform → Outperform | $8 |
| 2025-09-25 | main | Stifel | Buy → Buy | $12 |
| 2025-09-25 | main | Wedbush | Outperform → Outperform | $9 |
| 2025-09-25 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-09-24 | reit | Guggenheim | Buy → Buy | $6 |
| 2025-09-09 | init | Guggenheim | — → Buy | $6 |
| 2025-05-29 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-02-24 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-01-30 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-12-16 | down | B of A Securities | Neutral → Underperform | $3 |
| 2024-11-18 | main | B of A Securities | Neutral → Neutral | $6 |
| 2024-11-08 | main | Wedbush | Outperform → Outperform | $12 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-07-31 | reit | Wedbush | Outperform → Outperform | $20 |
- $PEPG stock is up 20% today. Here's what we see in our data. - Quiver Quantitative Mon, 27 Oct 2025 07
- How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44% - Yahoo Finance Wed, 10 Dec 2025 08
- PepGen (PEPG) Price Target Increased by 17.65% to 10.20 - Nasdaq Sun, 16 Nov 2025 08
- PepGen: DMD Discontinued, Ways To Go With DM1 (NASDAQ:PEPG) - Seeking Alpha ue, 07 Oct 2025 07
- Why Is PepGen Stock (PEPG) Up 125% Today? - TipRanks hu, 25 Sep 2025 07
- Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans? - simplywall.st Wed, 19 Nov 2025 08
- PepGen Stock More Than Doubles On Thursday – Check Out The New Price Targets On Wall Street - Stocktwits hu, 25 Sep 2025 14
- $PEPG stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Mon, 01 Dec 2025 08
- BofA Lifts PepGen (PEPG) PT to $3 on Positive DM1 Data Despite Underperform Rating - Yahoo Finance Sun, 26 Oct 2025 07
- MODD, GALT, XCUR, PEPG, BSGM Stocks Pop After Hours On Clinical Updates And Strategic Moves - Nasdaq Fri, 12 Sep 2025 07
- PepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM Data - Yahoo Finance ue, 30 Sep 2025 07
- PepGen (PEPG) Skyrockets 121% on Stellar Experimental Treatment Trial Results - Yahoo Finance Fri, 26 Sep 2025 07
- Insider Purchase: Director at $PEPG Buys 9,375,000 Shares | PEPG Stock News - Quiver Quantitative ue, 30 Sep 2025 07
- Can PepGen (NASDAQ:PEPG) Afford To Invest In Growth? - Yahoo Finance Mon, 22 Sep 2025 07
- PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles - Yahoo Finance hu, 25 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 35000 | — | — | Stock Award(Grant) at price 0.00 per share. | VITTIGLIO JOSEPH D | Officer | — | 2025-12-08 00:00:00 | D |
| 1 | 200000 | 924000 | — | Purchase at price 4.62 per share. | OXFORD SCIENCES ENTERPRISES PLC | Unknown | — | 2025-09-30 00:00:00 | D |
| 2 | 9375000 | 47531250 | — | Purchase at price 5.07 per share. | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-26 00:00:00 | I |
| 3 | 8375 | 10393 | — | Purchase at price 1.24 per share. | STRECK PAUL | Officer | — | 2025-05-30 00:00:00 | D |
| 4 | 16750 | — | — | Stock Award(Grant) at price 0.00 per share. | KASRA KASRAIAN | Chief Technology Officer | — | 2025-05-20 00:00:00 | D |
| 5 | 10000 | 13550 | — | Purchase at price 1.36 per share. | MCARTHUR JAMES G | Chief Executive Officer | — | 2025-04-17 00:00:00 | D |
| 6 | 41500 | 47725 | — | Purchase at price 1.15 per share. | MCARTHUR JAMES G | Chief Executive Officer | — | 2025-04-08 00:00:00 | D |
| 7 | 19430 | — | — | Stock Award(Grant) at price 0.00 per share. | STRECK PAUL | Officer | — | 2025-03-03 00:00:00 | D |
| 8 | 60719 | — | — | Stock Award(Grant) at price 0.00 per share. | MCARTHUR JAMES G | Chief Executive Officer | — | 2025-03-03 00:00:00 | D |
| 9 | 23283 | — | — | Stock Award(Grant) at price 0.00 per share. | DONNELLY NOEL | Chief Financial Officer | — | 2025-03-03 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.01 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -92.49M | -83.92M | -67.81M | -26.93M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -89.98M | -78.63M | -69.10M | -27.28M |
| ReconciledDepreciation | 5.25M | 850.00K | 493.00K | 178.00K |
| EBITDA | -92.49M | -83.92M | -67.81M | -26.93M |
| EBIT | -97.74M | -84.77M | -68.30M | -27.11M |
| NetInterestIncome | 7.14M | 6.40M | 2.79M | 0.00 |
| InterestIncome | 7.14M | 6.40M | 2.79M | 0.00 |
| NormalizedIncome | -89.98M | -78.63M | -69.10M | -27.28M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -89.98M | -78.63M | -69.10M | -27.28M |
| TotalExpenses | 97.74M | 84.77M | 68.30M | 27.11M |
| TotalOperatingIncomeAsReported | -97.74M | -84.77M | -68.30M | -27.11M |
| DilutedAverageShares | 31.58M | 23.80M | 23.71M | 7.72M |
| BasicAverageShares | 31.58M | 23.80M | 23.71M | 7.72M |
| DilutedEPS | -2.85 | -3.30 | -2.91 | -3.53 |
| BasicEPS | -2.85 | -3.30 | -2.91 | -3.53 |
| DilutedNIAvailtoComStockholders | -89.98M | -78.63M | -69.10M | -27.28M |
| NetIncomeCommonStockholders | -89.98M | -78.63M | -69.10M | -27.28M |
| OtherunderPreferredStockDividend | -196.00K | |||
| NetIncome | -89.98M | -78.63M | -69.10M | -27.28M |
| NetIncomeIncludingNoncontrollingInterests | -89.98M | -78.63M | -69.10M | -27.28M |
| NetIncomeContinuousOperations | -89.98M | -78.63M | -69.10M | -27.28M |
| TaxProvision | -617.00K | 73.00K | 3.71M | 0.00 |
| PretaxIncome | -90.60M | -78.55M | -65.40M | -27.28M |
| OtherIncomeExpense | -1.00K | -187.00K | 110.00K | -172.00K |
| OtherNonOperatingIncomeExpenses | -1.00K | -187.00K | 110.00K | -172.00K |
| NetNonOperatingInterestIncomeExpense | 7.14M | 6.40M | 2.79M | 0.00 |
| InterestIncomeNonOperating | 7.14M | 6.40M | 2.79M | 0.00 |
| OperatingIncome | -97.74M | -84.77M | -68.30M | -27.11M |
| OperatingExpense | 97.74M | 84.77M | 68.30M | 27.11M |
| ResearchAndDevelopment | 76.48M | 68.13M | 54.08M | 19.00M |
| SellingGeneralAndAdministration | 21.26M | 16.64M | 14.22M | 8.11M |
| GeneralAndAdministrativeExpense | 21.26M | 16.64M | 14.22M | 8.11M |
| OtherGandA | 21.26M | 16.64M | 14.22M | 8.11M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 32.62M | 23.82M | 23.71M | 20.56M |
| ShareIssued | 32.62M | 23.82M | 23.71M | 20.56M |
| TotalDebt | 18.66M | 20.10M | 24.53M | 0.00 |
| TangibleBookValue | 118.62M | 108.42M | 179.63M | -32.08M |
| InvestedCapital | 118.62M | 108.42M | 179.63M | -32.08M |
| WorkingCapital | 107.06M | 95.15M | 167.25M | 129.66M |
| NetTangibleAssets | 118.62M | 108.42M | 179.63M | 133.09M |
| CapitalLeaseObligations | 18.66M | 20.10M | 24.53M | 0.00 |
| CommonStockEquity | 118.62M | 108.42M | 179.63M | -32.08M |
| PreferredStockEquity | 165.18M | |||
| TotalCapitalization | 118.62M | 108.42M | 179.63M | 133.09M |
| TotalEquityGrossMinorityInterest | 118.62M | 108.42M | 179.63M | 133.09M |
| StockholdersEquity | 118.62M | 108.42M | 179.63M | 133.09M |
| GainsLossesNotAffectingRetainedEarnings | 23.00K | 34.00K | -81.00K | 17.00K |
| OtherEquityAdjustments | 23.00K | 34.00K | -81.00K | 17.00K |
| RetainedEarnings | -271.46M | -181.48M | -102.86M | -33.75M |
| AdditionalPaidInCapital | 390.06M | 289.87M | 282.57M | 1.65M |
| CapitalStock | 3.00K | 2.00K | 2.00K | 165.18M |
| CommonStock | 3.00K | 2.00K | 2.00K | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 165.18M |
| TotalLiabilitiesNetMinorityInterest | 32.26M | 34.63M | 37.81M | 10.55M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 15.57M | 17.10M | 18.98M | 226.00K |
| DerivativeProductLiabilities | 0.00 | 226.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 15.57M | 17.10M | 18.98M | 0.00 |
| LongTermCapitalLeaseObligation | 15.57M | 17.10M | 18.98M | 0.00 |
| CurrentLiabilities | 16.70M | 17.53M | 18.83M | 10.32M |
| CurrentDebtAndCapitalLeaseObligation | 3.09M | 3.00M | 5.55M | |
| CurrentCapitalLeaseObligation | 3.09M | 3.00M | 5.55M | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.62M | 2.37M | 2.44M | 1.21M |
| PayablesAndAccruedExpenses | 9.98M | 12.16M | 10.84M | 9.12M |
| CurrentAccruedExpenses | 8.23M | 11.15M | 6.90M | 5.88M |
| Payables | 1.75M | 1.00M | 3.94M | 3.24M |
| TotalTaxPayable | 0.00 | 2.57M | 0.00 | |
| AccountsPayable | 1.75M | 1.00M | 1.36M | 3.24M |
| TotalAssets | 150.88M | 143.05M | 217.44M | 143.64M |
| TotalNonCurrentAssets | 27.12M | 30.37M | 31.36M | 3.65M |
| OtherNonCurrentAssets | 1.97M | 1.99M | 1.47M | 3.02M |
| NetPPE | 25.15M | 28.38M | 29.88M | 636.00K |
| AccumulatedDepreciation | -3.05M | -1.57M | -389.00K | -430.00K |
| GrossPPE | 28.19M | 29.96M | 30.27M | 1.07M |
| Leases | 23.62M | 26.55M | ||
| ConstructionInProgress | 96.00K | 69.00K | 1.13M | 0.00 |
| OtherProperties | 26.54M | 28.44M | 2.42M | 975.00K |
| MachineryFurnitureEquipment | 1.56M | 1.45M | 171.00K | 91.00K |
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 123.76M | 112.68M | 186.08M | 139.99M |
| OtherCurrentAssets | 3.57M | 2.27M | 4.33M | 2.35M |
| PrepaidAssets | 2.35M | |||
| Receivables | 58.00K | 4.74M | ||
| OtherReceivables | 58.00K | 4.74M | ||
| CashCashEquivalentsAndShortTermInvestments | 120.19M | 110.41M | 181.75M | 132.90M |
| OtherShortTermInvestments | 70.77M | 29.63M | 0.00 | |
| CashAndCashEquivalents | 49.42M | 80.77M | 181.75M | 132.90M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -82.87M | -71.60M | -63.02M | -23.10M |
| IssuanceOfCapitalStock | 86.78M | 0.00 | 114.27M | 149.04M |
| CapitalExpenditure | -497.00K | -2.60M | -3.75M | -500.00K |
| IncomeTaxPaidSupplementalData | 71.00K | 2.70M | 0.00 | |
| EndCashPosition | 50.97M | 82.32M | 183.22M | 134.37M |
| BeginningCashPosition | 82.32M | 183.22M | 134.37M | 9.78M |
| EffectOfExchangeRateChanges | -62.00K | 286.00K | -316.00K | 33.00K |
| ChangesInCash | -31.29M | -101.19M | 49.17M | 124.56M |
| FinancingCashFlow | 88.75M | -189.00K | 112.19M | 147.66M |
| CashFlowFromContinuingFinancingActivities | 88.75M | -189.00K | 112.19M | 147.66M |
| NetOtherFinancingCharges | -511.00K | -442.00K | -2.70M | -1.39M |
| ProceedsFromStockOptionExercised | 2.48M | 253.00K | 623.00K | 0.00 |
| NetPreferredStockIssuance | 0.00 | 149.04M | ||
| PreferredStockIssuance | 0.00 | 149.04M | ||
| NetCommonStockIssuance | 86.78M | 0.00 | 114.27M | 0.00 |
| CommonStockIssuance | 86.78M | 0.00 | 114.27M | 0.00 |
| InvestingCashFlow | -37.67M | -32.00M | -3.75M | -500.00K |
| CashFlowFromContinuingInvestingActivities | -37.67M | -32.00M | -3.75M | -500.00K |
| NetInvestmentPurchaseAndSale | -37.17M | -29.40M | 0.00 | |
| SaleOfInvestment | 108.00M | 0.00 | ||
| PurchaseOfInvestment | -145.17M | -29.40M | 0.00 | |
| NetPPEPurchaseAndSale | -497.00K | -2.60M | -3.75M | -500.00K |
| PurchaseOfPPE | -497.00K | -2.60M | -3.75M | -500.00K |
| OperatingCashFlow | -82.37M | -69.00M | -59.27M | -22.60M |
| CashFlowFromContinuingOperatingActivities | -82.37M | -69.00M | -59.27M | -22.60M |
| ChangeInWorkingCapital | -5.25M | 1.95M | 4.51M | 2.77M |
| ChangeInOtherCurrentLiabilities | -3.00M | -1.17M | -2.02M | 0.00 |
| ChangeInOtherCurrentAssets | 0.00 | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | -941.00K | 1.05M | 4.12M | 9.33M |
| ChangeInAccruedExpense | -1.66M | 1.42M | 5.53M | 6.82M |
| ChangeInPayable | 722.00K | -369.00K | -1.41M | 2.51M |
| ChangeInAccountPayable | 722.00K | -369.00K | -1.41M | 2.51M |
| ChangeInPrepaidAssets | -1.30M | 2.06M | -1.78M | -2.21M |
| ChangeInReceivables | 26.00K | 4.18M | -4.34M | |
| OtherNonCashItems | 70.00K | 134.00K | ||
| StockBasedCompensation | 11.46M | 7.05M | 4.76M | 1.53M |
| AmortizationOfSecurities | -3.92M | -220.00K | 0.00 | |
| DepreciationAmortizationDepletion | 5.25M | 850.00K | 493.00K | 178.00K |
| DepreciationAndAmortization | 5.25M | 850.00K | 493.00K | 178.00K |
| AmortizationCashFlow | 3.75M | -334.00K | 0.00 | |
| AmortizationOfIntangibles | 3.75M | -334.00K | 0.00 | |
| Depreciation | 1.50M | 1.18M | 493.00K | 178.00K |
| OperatingGainsLosses | 76.00K | 196.00K | ||
| GainLossOnInvestmentSecurities | -58.00K | 196.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 134.00K | ||
| NetIncomeFromContinuingOperations | -89.98M | -78.63M | -69.10M | -27.28M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PEPG
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|